Monitor enrollment updates for the PROPEL-IPF Phase 2 trial and any data readouts for PIPE-791 in IPF or chronic pain. The cash runway through mid-2029 removes near-term financing risk, but the widening loss reflects increased trial spending with no revenue on the horizon.
Drugs in focus
CTNM drug pipeline →PIPE-791
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 4-5 years away, if successful. The Phase 2 PROPEL-IPF trial is estimated to complete in June 2028, and a Phase 3 program and regulatory filing would follow, meaning potential approval is likely in the 2030-2032 timeframe at the earliest.
- Next catalyst
- None dated
What to watchPIPE-791 is a mid-stage asset with no near-term binary catalyst; the next major event is the Phase 2 PROPEL-IPF readout estimated for mid-2028. The competitive landscape shifted significantly on October 12, 2026, when BMS's admilparant succeeded in Phase 3 for IPF, potentially becoming the first approved LPAR1 antagonist. Investors should watch for enrollment completion updates and whether Contineum can differentiate PIPE-791 on safety, dosing convenience, or CNS indications (chronic pain, MS) where BMS's compound may not compete.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $9.79entry
- T+1 · 12d ago −10.01%α −5.60% · $8.81
- T+5 · 6d ago +10.01%α +10.92% · $10.77
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Contineum Therapeutics reported Q3 2026 financial results with a net loss of $18.7M, wider than the $12.8M loss in Q3 2025, driven by a 45% increase in R&D expenses to $16.0M for the PIPE-791 IPF program. Cash and securities stood at $244.5M, with a projected runway through mid-2029. No revenue or EPS consensus beat/miss is applicable as the company is a pre-revenue clinical-stage biotech.
Key Financial Metrics
Key Facts
- Net loss of $18.7M for Q3 2026 vs $12.8M in Q3 2025
- R&D expenses $16.0M, up 45% YoY driven by PIPE-791 IPF program
- Cash, cash equivalents and marketable securities $244.5M as of Sep 30, 2026
- Cash runway projected through mid-2029, one year past estimated IPF trial completion
- PROPEL-IPF Phase 2 trial for PIPE-791 has over 100 sites in 16 countries
- Weighted-average diluted shares 38,390,234 in Q3 2026 vs 28,115,548 in Q3 2025
Financial Impact
Net loss widened by $5.9M YoY; cash burn $18.7M per quarter; cash runway through mid-2029
Risk Factors
- No approved products or revenue; dependent on clinical trial success
- Heavy reliance on PIPE-791 and PIPE-307, both in early clinical stages
- R&D expenses expected to continue increasing significantly
- Reliance on Janssen/Johnson & Johnson for PIPE-307 development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-069493 |
| Document: ctnm-20261103.htm | 0001628280-26-069493 |
| Document: 0001628280-26-069493-index-headers.html | 0001628280-26-069493 |
| Document: 0001628280-26-069493-index.html | 0001628280-26-069493 |
| Document: 0001628280-26-069493.txt | 0001628280-26-069493 |
| 8-K Data (Synthetic) | 0001628280-26-069493 |
Track record
14 reports on CTNM
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $9.72 Now $9.67 −0.46% settles Dec 15
- Nov 10, 20266d ago Institutional Cluster Neutral 2/10 Entry $10.56 Now $9.67 −8.43% settles Dec 9
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.52 Now $9.67 +1.58% settles Dec 7
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $8.81 Now $9.67 +9.76% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $8.81 Now $9.67 +9.76% settles Dec 4
- Nov 3, 202613d ago 8-K Neutral 3/10 Viewing Entry $9.79 Now $9.67 −1.23% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 3/10 Entry $9.33 Now $9.67 +3.64% settles Nov 27
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $9.15 Now $9.67 +5.68% settles Nov 25
- Oct 22, 202625d ago SC 13G Neutral 3/10 Entry $8.31 Now $9.67 +16.37% settles Nov 20
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $13.40 to $8.46 Now $9.67 −27.84% ▼ −36.87% −36.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers